Autism spectrum disorder market across 7MM to reach $2 billion by 2034
The autism spectrum disorder (ASD) market across the seven major markets (7MM: USA, France, Germany, Italy, Spain and Japan) is projected to grow at a compound annual growth rate (CAGR) of 18.7%, from $364.9 million in 2024 to $2.0 billion in 2034, according to pharma analytics company GlobalData.
GlobalData’s latest report, “Autism Spectrum Disorder: Opportunity Assessment and Forecast” reveals that the significant growth in the market will be driven by the anticipated launches of five late-stage pipeline products during the forecast period.
ASD refers to a broad range of conditions characterized by challenges with social communication and repetitive behavioral patterns. These are the core symptoms of ASD that can affect the individual's ability to function in school, work, and other areas of life. There are currently no approved pharmacological therapies to target the core symptoms, so each symptom individually constitutes a significant unmet need for therapeutic intervention, warranting targeted drug development.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
| Headless Content Management with Blaze